MedTrace Logo

Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer

NCT05427617 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 223

Last updated 2022-06-22

No results posted yet for this study

Summary

This is a retrospective, observational, multi-center clinical study of circulating tumor DNA (ctDNA) to guide late-line therapy in late-stage metastatic breast cancer patients.

Conditions

Interventions

DRUG

Control group

Physician chosen treatment

DRUG

Case group

Druggable ctDNA alterations-guided therapy

Sponsors & Collaborators

  • Hunan Cancer Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-01
Primary Completion
2019-06-30
Completion
2021-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05427617 on ClinicalTrials.gov